Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people.

Gimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M, Dudley J, Emma F, Konrad M, Harris T, Harris PC, König J, Liebau MC, Marlais M, Mekahli D, Metcalfe AM, Oh J, Perrone RD, Sinha MD, Titieni A, Torra R, Weber S, Winyard PJD, Schaefer F.

Nat Rev Nephrol. 2019 May 22. doi: 10.1038/s41581-019-0155-2. [Epub ahead of print] Review.

PMID:
31118499
2.

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.

Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE.

Eur J Pediatr. 2019 Jul;178(7):1013-1021. doi: 10.1007/s00431-019-03384-x. Epub 2019 May 3.

3.

Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome.

Warejko JK, Tan W, Daga A, Schapiro D, Lawson JA, Shril S, Lovric S, Ashraf S, Rao J, Hermle T, Jobst-Schwan T, Widmeier E, Majmundar AJ, Schneider R, Gee HY, Schmidt JM, Vivante A, van der Ven AT, Ityel H, Chen J, Sadowski CE, Kohl S, Pabst WL, Nakayama M, Somers MJG, Rodig NM, Daouk G, Baum M, Stein DR, Ferguson MA, Traum AZ, Soliman NA, Kari JA, El Desoky S, Fathy H, Zenker M, Bakkaloglu SA, Müller D, Noyan A, Ozaltin F, Cadnapaphornchai MA, Hashmi S, Hopcian J, Kopp JB, Benador N, Bockenhauer D, Bogdanovic R, Stajić N, Chernin G, Ettenger R, Fehrenbach H, Kemper M, Munarriz RL, Podracka L, Büscher R, Serdaroglu E, Tasic V, Mane S, Lifton RP, Braun DA, Hildebrandt F.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):53-62. doi: 10.2215/CJN.04120417. Epub 2017 Nov 10.

4.

Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease.

Cadnapaphornchai MA.

Front Pediatr. 2017 Mar 23;5:53. doi: 10.3389/fped.2017.00053. eCollection 2017. Review.

5.

Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.

Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M.

Nephrol Dial Transplant. 2017 Feb 1;32(2):342-347. doi: 10.1093/ndt/gfw013.

6.

Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B.

Am J Nephrol. 2016;44(3):171-8. doi: 10.1159/000448695. Epub 2016 Aug 23.

7.

Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.

Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA.

Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1534-41. doi: 10.2215/CJN.11331114. Epub 2015 Jul 29.

8.

Intravenous acyclovir and renal dysfunction in children: a matched case control study.

Rao S, Abzug MJ, Carosone-Link P, Peterson T, Child J, Siparksy G, Soranno D, Cadnapaphornchai MA, Simões EA.

J Pediatr. 2015 Jun;166(6):1462-8.e1-4. doi: 10.1016/j.jpeds.2015.01.023. Epub 2015 Feb 21.

PMID:
25708691
9.

Autosomal dominant polycystic kidney disease in children.

Cadnapaphornchai MA.

Curr Opin Pediatr. 2015 Apr;27(2):193-200. doi: 10.1097/MOP.0000000000000195. Review.

10.

Endothelial dysfunction and oxidative stress in polycystic kidney disease.

Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW.

Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1198-206. doi: 10.1152/ajprenal.00327.2014. Epub 2014 Sep 18.

11.

Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference.

Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, Cadnapaphornchai MA, Dell KM, Kerecuk L, Liebau MC, Alonso-Peclet MH, Shneider B, Emre S, Heller T, Kamath BM, Murray KF, Moise K, Eichenwald EE, Evans J, Keller RL, Wilkins-Haug L, Bergmann C, Gunay-Aygun M, Hooper SR, Hardy KK, Hartung EA, Streisand R, Perrone R, Moxey-Mims M.

J Pediatr. 2014 Sep;165(3):611-7. doi: 10.1016/j.jpeds.2014.06.015. Epub 2014 Jul 9. No abstract available.

12.

Predictors of autosomal dominant polycystic kidney disease progression.

Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S.

J Am Soc Nephrol. 2014 Nov;25(11):2399-418. doi: 10.1681/ASN.2013111184. Epub 2014 Jun 12. Review.

13.

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW.

Clin J Am Soc Nephrol. 2014 May;9(5):889-96. doi: 10.2215/CJN.08350813. Epub 2014 Apr 10.

14.

Bioactive lipid mediators in polycystic kidney disease.

Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW.

J Lipid Res. 2014 Jun;55(6):1139-49. doi: 10.1194/jlr.P042176. Epub 2013 Dec 16.

15.

Renal relevant radiology: use of ultrasonography in patients with AKI.

Faubel S, Patel NU, Lockhart ME, Cadnapaphornchai MA.

Clin J Am Soc Nephrol. 2014 Feb;9(2):382-94. doi: 10.2215/CJN.04840513. Epub 2013 Nov 14. Review.

16.

The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications.

Cadnapaphornchai MA, Tkachenko O, Shchekochikhin D, Schrier RW.

Pediatr Nephrol. 2014 Jul;29(7):1159-67. doi: 10.1007/s00467-013-2567-8. Epub 2013 Aug 30. Review.

PMID:
23989393
17.

Hypertension in children with autosomal dominant polycystic kidney disease (ADPKD).

Cadnapaphornchai MA.

Curr Hypertens Rev. 2013 Feb;9(1):21-6. Review.

PMID:
23971640
18.

Strategies for the preservation of residual renal function in pediatric dialysis patients.

Cadnapaphornchai MA, Teitelbaum I.

Pediatr Nephrol. 2014 May;29(5):825-36; quiz 832. doi: 10.1007/s00467-013-2554-0. Epub 2013 Jul 19. Review.

PMID:
23868107
19.

Efficacy and safety of clopidogrel in children with diarrhea associated hemolytic uremic syndrome.

Seltz LB, Bakel LA, Tiehen J, Gao D, Cadnapaphornchai MA, Lum G, Ford D.

Thromb Res. 2012 Sep;130(3):e26-30. doi: 10.1016/j.thromres.2012.05.017. Epub 2012 Jun 8.

PMID:
22683020
20.

Persistent elevation of urine aquaporin-2 during water loading in a child with nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a R137L mutation in the V2 vasopressin receptor.

Cheung CC, Cadnapaphornchai MA, Ranadive SA, Gitelman SE, Rosenthal SM.

Int J Pediatr Endocrinol. 2012 Feb 10;2012(1):3. doi: 10.1186/1687-9856-2012-3.

21.

Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.

Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW.

Contemp Clin Trials. 2011 May;32(3):437-45. doi: 10.1016/j.cct.2011.01.008. Epub 2011 Jan 23.

22.

Magnetic resonance imaging of kidney and cyst volume in children with ADPKD.

Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW.

Clin J Am Soc Nephrol. 2011 Feb;6(2):369-76. doi: 10.2215/CJN.03780410. Epub 2010 Nov 29.

23.

Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery.

Dennen P, Altmann C, Kaufman J, Klein CL, Andres-Hernando A, Ahuja NH, Edelstein CL, Cadnapaphornchai MA, Keniston A, Faubel S.

Crit Care. 2010;14(5):R181. doi: 10.1186/cc9289. Epub 2010 Oct 13.

24.

Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.

Reed BY, Masoumi A, Elhassan E, McFann K, Cadnapaphornchai MA, Maahs DM, Snell-Bergeon JK, Schrier RW.

Kidney Int. 2011 Jan;79(1):128-34. doi: 10.1038/ki.2010.355. Epub 2010 Sep 29.

25.

Evidence of extraordinary growth in the progressive enlargement of renal cysts.

Grantham JJ, Cook LT, Wetzel LH, Cadnapaphornchai MA, Bae KT.

Clin J Am Soc Nephrol. 2010 May;5(5):889-96. doi: 10.2215/CJN.00550110. Epub 2010 Apr 1.

26.

Case report: severe neonatal hyperkalemia due to pseudohypoaldosteronism type 1.

Schweiger B, Moriarty MW, Cadnapaphornchai MA.

Curr Opin Pediatr. 2009 Apr;21(2):269-71. doi: 10.1097/MOP.0b013e328325a55f.

PMID:
19657313
27.

Prospective change in renal volume and function in children with ADPKD.

Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW.

Clin J Am Soc Nephrol. 2009 Apr;4(4):820-9. doi: 10.2215/CJN.02810608.

28.

Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension.

Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW.

Kidney Int. 2008 Nov;74(9):1192-6. doi: 10.1038/ki.2008.397. Epub 2008 Aug 20.

29.

An unusual cause of pediatric hypertension.

Friedman K, Wallis T, Maloney KW, Hendrickson RJ, Mengshol S, Cadnapaphornchai MA.

J Pediatr. 2007 Aug;151(2):206-12. No abstract available.

PMID:
17643780
30.

Hyperosmolality in vivo upregulates aquaporin 2 water channel and Na-K-2Cl co-transporter in Brattleboro rats.

Li C, Wang W, Summer SN, Cadnapaphornchai MA, Falk S, Umenishi F, Schrier RW.

J Am Soc Nephrol. 2006 Jun;17(6):1657-64. Epub 2006 May 3.

31.

Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency.

Wang W, Li C, Summer SN, Falk S, Cadnapaphornchai MA, Chen YC, Schrier RW.

Am J Physiol Renal Physiol. 2006 May;290(5):F1135-42. Epub 2005 Dec 13.

32.

Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats.

Chen YC, Cadnapaphornchai MA, Summer SN, Falk S, Li C, Wang W, Schrier RW.

J Am Soc Nephrol. 2005 Oct;16(10):2864-71. Epub 2005 Aug 17.

33.

Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism.

Chen YC, Cadnapaphornchai MA, Yang J, Summer SN, Falk S, Li C, Wang W, Schrier RW.

Am J Physiol Renal Physiol. 2005 Oct;289(4):F672-8. Epub 2005 May 24.

34.

Clinical update on renal aquaporins.

Chen YC, Cadnapaphornchai MA, Schrier RW.

Biol Cell. 2005 Jun;97(6):357-71. Review.

PMID:
15901245
35.

Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).

Cadnapaphornchai MA, Fick-Brosnahan GM, Duley I, Johnson AM, Strain JD, DeGroff CG, Schrier RW.

Contemp Clin Trials. 2005 Apr;26(2):211-22.

PMID:
15837441
36.

From finch to fish to man: role of aquaporins in body fluid and brain water regulation.

Schrier RW, Chen YC, Cadnapaphornchai MA.

Neuroscience. 2004;129(4):897-904. Review.

PMID:
15561406
37.

Evidence for bradykinin as a stimulator of thirst.

Cadnapaphornchai MA, Rogachev B, Summer SN, Chen YC, Gera L, Stewart JM, Schrier RW.

Am J Physiol Renal Physiol. 2004 May;286(5):F875-80. Epub 2004 Jan 6.

38.

Effect of primary polydipsia on aquaporin and sodium transporter abundance.

Cadnapaphornchai MA, Summer SN, Falk S, Thurman JM, Knepper MA, Schrier RW.

Am J Physiol Renal Physiol. 2003 Nov;285(5):F965-71. Epub 2003 Jul 22.

39.

Urinary concentrating defect in hypothyroid rats: role of sodium, potassium, 2-chloride co-transporter, and aquaporins.

Cadnapaphornchai MA, Kim YW, Gurevich AK, Summer SN, Falk S, Thurman JM, Schrier RW.

J Am Soc Nephrol. 2003 Mar;14(3):566-74.

40.

Renal aquaporin water channels: from molecules to human disease.

Schrier RW, Cadnapaphornchai MA.

Prog Biophys Mol Biol. 2003 Feb;81(2):117-31. Review.

PMID:
12565698
41.

Effect of mineralocorticoid deficiency on ion and urea transporters and aquaporin water channels in the rat.

Ohara M, Cadnapaphornchai MA, Summer SN, Falk S, Yang J, Togawa T, Schrier RW.

Biochem Biophys Res Commun. 2002 Nov 29;299(2):285-90.

PMID:
12437984
42.

Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists.

Schrier RW, Cadnapaphornchai MA, Umenishi F.

Heart Dis. 2001 May-Jun;3(3):210-4. Review.

PMID:
11975794
43.

Pathophysiology of sodium and water retention in heart failure.

Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW.

Cardiology. 2001;96(3-4):122-31.

PMID:
11805379
44.

Water retention and aquaporins in heart failure, liver disease and pregnancy.

Schrier RW, Cadnapaphornchai MA, Ohara M.

J R Soc Med. 2001 Jun;94(6):265-9. Review. No abstract available.

45.

Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy.

Cadnapaphornchai MA, Ohara M, Morris KG Jr, Knotek M, Rogachev B, Ladtkow T, Carter EP, Schrier RW.

Am J Physiol Renal Physiol. 2001 Apr;280(4):F592-8.

46.

Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis.

Schrier RW, Gurevich AK, Cadnapaphornchai MA.

Semin Nephrol. 2001 Mar;21(2):157-72. Review.

PMID:
11245778
47.

Pathogenesis and management of hyponatremia.

Cadnapaphornchai MA, Schrier RW.

Am J Med. 2000 Dec 1;109(8):688-92. No abstract available.

PMID:
11099692
48.

Cystic renal lymphangiectasia presenting as renal insufficiency in childhood.

Cadnapaphornchai MA, Ford DM, Tyson RW, Lum GM.

Pediatr Nephrol. 2000 Nov;15(1-2):129-31.

PMID:
11095029
49.

Hypocomplementemic urticarial vasculitis: report of a pediatric case.

Cadnapaphornchai MA, Saulsbury FT, Norwood VF.

Pediatr Nephrol. 2000 Apr;14(4):328-31.

PMID:
10775080

Supplemental Content

Loading ...
Support Center